RT Journal Article
SR Electronic
T1 SARS-CoV2- infection as a trigger of humoral response against apolipoprotein A-1
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.12.21251298
DO 10.1101/2021.02.12.21251298
A1 Pagano, Sabrina
A1 Yerly, Sabine
A1 Meyer, Benjamin
A1 Juillard, Catherine
A1 Suh, Noémie
A1 Terrier, Christophe Le
A1 Daguer, Jean-Pierre
A1 Farrera-Soler, Lluc
A1 Barluenga, Sofia
A1 Piumatti, Giovanni
A1 Hartley, Oliver
A1 Lemaitre, Barbara
A1 Eberhardt, Christiane S.
A1 Siegrist, Claire-Anne
A1 Eckerle, Isabella
A1 Stringhini, Silvia
A1 Guessous, Idris
A1 Kaiser, Laurent
A1 Pugin, Jerome
A1 Winssinger, Nicolas
A1 Vuilleumier, Nicolas
YR 2021
UL http://medrxiv.org/content/early/2021/05/07/2021.02.12.21251298.abstract
AB Aims Unravelling autoimmune targets triggered by SARS-CoV-2 infection may provide crucial insights in the physiopathology of the disease and foster the development of potential therapeutic candidate targets and prognostic tools. We aimed at determining i) the association between anti-SARS-CoV-2 and anti-apoA-1 humoral response, ii) their relationship to prognosis, and iii) the degree of linear homology between SARS-CoV-2, apoA-1, and Toll-like receptor-2 (TLR2) epitopes.Methods and Results Immunoreactivity against different engineered peptides as well as cytokines were assessed by immunoassays, on a case-control (n=101), an intensive care unit (ICU; n=126) with a 28-days follow-up, and a general population cohort (n=663) with available samples in the pre and post-pandemic period. Using bioinformatics modelling a linear sequence homologies between apoA-1, TLR2, and Spike epitopes were identified. Overall, anti-apoA-1IgG levels were higher in COVID-19 patients or anti-SARS-CoV-2 seropositive individuals than in healthy donors or anti-SARS-CoV-2 seronegative individuals (p<0.0001). Significant and similar associations were noted between anti-apoA-1, anti-SARS-CoV-2IgG, cytokines, and lipid profile. In ICU patients, anti-SARS-CoV-2 and anti-apoA-1 seroconversion rates displayed similar 7-days kinetics, reaching 82% for anti-apoA-1 seropositivity. C-statistics (CS) indicated that anti-Spike/TLR2 mimic-peptide IgGs displayed a significant prognostic accuracy for overall mortality at 28 days (CS: 0.64; p=0.02). In the general population, SARS-CoV-2 exposure increased baseline anti-apoA-1 IgG levels.Conclusion COVID-19 induces a marked humoral response against the major protein of high-density lipoproteins. As a correlate of poorer prognosis in other clinical settings, such autoimmunity signatures may relate to long-term COVID-19 prognosis assessment and warrant further scrutiny in the current COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Swiss Federal Office of Public Health, Swiss School of Public Health (Corona Immunitas research program), the Fondation de Bienfaisance du Groupe Pictet, the Fondation Ancrage, HUG private foundation, and the Center for Emerging Viral Diseases. The De Reuter (grant Nr 657) and the Schmidheiny Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Geneva Ethic Council for Research (CCER) (Protocoles Nr: CCER 2020-00917 and CCER16-363), and written informed consent was obtained by patients prior enrollment. CCER, Rue Adrien-Lachenal 8, 1207 Geneva, Switzerland. ccer{at}etat.ge.ch All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.